Ultragenyx sells some royalties on Crysvita to OMERS Life Sciences
Ultragenyx Pharmaceutical (RARE) has announced a transaction involving the sale of an additional 25% of its royalty interest from Kyowa Kirin. This deal, valued at $400 million, pertains to future sales of Crysvita (burosumab) in the U.S. and Canada,...
Seeking Alpha